Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms

NCT01112644 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

205

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Idiopathic RLS With Daytime Symptoms

Interventions

DRUG: Oxycodone naloxone prolonged release tablets (OXN PR)
OTHER: Placebo (PLA)

Sponsor

Mundipharma Research GmbH & Co KG